Contact:Jean-Louis Tayot,Director jltayot@imedex-bio.com

IMEDEX Biomatériaux is an independent privately held biotech company, incorporated in July 1998 as a spin off from PASTEUR-MERIEUX-CONNAUGHT and exclusively benefiting from a 10 years R& D program in the field of collagen biomaterials, representing an initial investment of $ 20 Million.

IMEDEX Biomatériaux (IMEDEX) develops proprietary collagen biomaterials to heal external or internal wounds. IMEDEX’s two lead development-stage products are designed to seal and to protect surgical wounds, stop bleedings, prevent blood, fluid and air leaks in a wide variety of tissues, attach prostheses, form anti-adhesion barriers and deliver therapeutics. In so doing, these products have the potential to significantly improve clinical outcomes and address large markets that are underserved by current commercial products.